Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$160.85 USD

160.85
485,338

-0.78 (-0.48%)

Updated Nov 12, 2024 04:00 PM ET

After-Market: $160.88 +0.03 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (66 out of 249)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Ecolab's Set to Report Q3 Earnings: What's in Store for the Stock?

by Zacks Equity Research

ECL third-quarter results are likely to reflect continued segmental strength.

Cardinal Health to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Despite recent supply chain challenges, new facilities and the acquisition of Specialty Networks are likely to have driven CAH's growth

Will Non-COVID-19 Diagnostics Sales Drive Hologic's Q4 Earnings?

by Zacks Equity Research

HOLX's fiscal 2024 fourth-quarter results are expected to reflect a solid performance of the Diagnostics business, led by the base Molecular franchise.

BSX Q3 Earnings Top, Stock Down in Premarket as Operating Margin Falls

by Zacks Equity Research

Boston Scientific registers year-over-year improvement in sales, indicating solid market share gains in legacy businesses despite macroeconomic odds.

Growing Biosimilars Business Supports ABT Stock, Macro Issues Hurt

by Zacks Equity Research

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

Transplant Logistic Service Business Likely to Aid TMDX's Q3 Earnings

by Zacks Equity Research

Expanding transplant logistic service business is likely to have driven TransMedics' third-quarter 2024 performance.

Will CGM Sensor Demand Continue to Drive DexCom Q3 Earnings?

by Zacks Equity Research

DXCM's third-quarter 2024 results are likely to reflect rising volumes across all channels.

AVTR Stock Flat Following the Close of Divestiture Deal With Audax

by Zacks Equity Research

Avantor closes its deal with Audax to divest its clinical services business.

Will Masimo (MASI) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

What's in Store for West Pharmaceutical in Q3 Earnings?

by Zacks Equity Research

WST's third-quarter 2024 results are likely to reflect weakness in its Proprietary Products business. Unfavorable currency movements might have hurt the top and bottom lines.

Henry Schein Stock Gains From Dental Business Expansion Amid Macro Woe

by Zacks Equity Research

Henry Schein strategically sets up distribution centers worldwide to better serve customers and increase its operating efficiency.

CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch

by Zacks Equity Research

Charles River launches Retrogenix Non-Human Protein Library to provide early insights into how therapeutics interact with non-human protein targets in vitro.

BRKR Stock to Gain From Newly Formed Bruker Spatial Biology Division

by Zacks Equity Research

Bruker announces the formation of the new Bruker Spatial Biology division.

Why Masimo (MASI) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

IDXX Gears Up for Q3 Earnings: What to Expect From the Stock?

by Zacks Equity Research

IDEXX Laboratories' third-quarter 2024 performance is expected to have benefited from a strong execution against strategic priorities.

Will FARAPULSE Line Aid Boston Scientific's Q3 Earnings?

by Zacks Equity Research

BSX is expected to have registered strong growth in the Asia Pacific, which is led by strength in China and Japan.

Edwards Lifesciences to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

EW is likely to have witnessed continued growth in TAVR procedures across the United States and worldwide in the third quarter.

Abbott's Q3 Earnings Release Coming Up, EPD Business in Focus

by Zacks Equity Research

ABT's Neuromodulation growth is expected to have been driven by strong demand in international markets for the Eterna rechargeable spinal cord stimulation device.

DGX Gears Up for Q3 Earnings: What Lies Ahead for the Stock?

by Zacks Equity Research

Quest Diagnostics is expected to deliver robust base business growth in the third quarter of 2024.

Labcorp's Q3 Earnings Looms: Here's What to Expect From the Stock

by Zacks Equity Research

LH is expected to perform strongly in both of its segments and will also likely advance in its strategic priorities.

Here's Why You Should Add Masimo Stock to Your Portfolio Now

by Zacks Equity Research

MASI's R&D activities raise optimism about the stock.

Reasons to Retain DexCom Stock in Your Portfolio for Now

by Zacks Equity Research

DXCM continues to raise optimism among investors, owing to its strong product portfolio.

Best Momentum Stocks to Buy for October 1st

by Zacks Equity Research

AU, MASI, and SKM made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 1, 2024.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Masimo (MASI) Surges 8.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

Masimo (MASI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.